Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Program Official
Principal Investigator
Jay W Carlson
Awardee Organization

Ozark Health Ventures, Llc
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO)

Ozark Health Ventures, LLC d/b/a Cancer Research for the Ozarks (CRO) is submitting this grant application as it desires to continue to be involved with the cooperative efforts of the NCI Community Oncology Research Program (NCORP) to focus on the broader needs of cancer prevention and treatment, cancer care delivery, imaging studies and cancer care of patients who live in rural regions of the network. Cancer Research for the Ozarks has a long and mutually beneficial history with the NCI for over 31 years of offering clinical trial access to rural communities within the central United States. Since its inception, CRO has grown from southwest Missouri, to increasing its network to 15 component sites that incorporate 42 counties in five states with a predominately rural population of more than 4,300,000. CRO would be the primary access for NCI-sponsored and NTCN network trials for the vast majority of these patients. CRO has been a significant contributor to enrollments in protocols involving cancer prevention and treatment, imaging studies, cancer care delivery studies, and tissue procurement protocols. CRO routinely meets the NCI criteria for enrollments and for the number of CCDR protocols it has open. CRO has a plan for further expansion of components and investigators to secure even higher enrollments. CRO participates with the following research bases: Alliance: member since June 2012; NRG: member since their merger in 2014 and the preceding legacy groups; SWOG: member since its inception in 1987; Wake Forest: member since their inception in 2014 and participated in protocols with the preceding Cancer Center; ECOG-ACRIN: member since 2014 and the preceding legacy groups. In addition, CRO has been involved in the Children’s Oncology Group at Mercy St. Louis since June 2011. The major collective strengths of the CRO application would be the tremendous support and commitment of the two primary components, the broad network of component sites, the quality, integrity and experience of CRO’s leadership and the program, and the many investigators and collaborators that it supports.

Publications

  • Chou SS, Romanoff J, Lehman CD, Khan SA, Carlos R, Badve SS, Xiao J, Corsetti RL, Javid SH, Spell DW, Han LK, Sabol JL, Bumberry JR, Gareen IF, Snyder BS, Gatsonis C, Wagner LI, Wolff AC, Miller KD, Sparano JA, Comstock CE, Rahbar H. Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). Radiology. 2021 Oct;301(1):66-77. Epub 2021 Aug 3. PMID: 34342501
  • Dunsmore VJ, Snyder BS, Gareen IF, Lehman CD, Khan SA, Romanoff J, Gatsonis C, Corsetti RL, Rahbar H, Spell DW, Han LK, Bumberry JR, Miller KD, Sparano JA, Comstock C, Park E, Wagner LI, Carlos RC. Quality of Life Among Patients With Ductal Carcinoma In Situ. JAMA network open. 2025 Jul 1;8(7):e2518887. PMID: 40608342
  • Sadigh G, Duan F, Gareen IF, Hancock J, Sicks JD, Hawley S, Shankaran V, Torres M, Wagner LI, Carlos RC. Effectiveness of out-of-pocket cost COMmunication and financial navigation (CostCOM) in cancer patients: Study protocol for ECOG-ACRIN EAQ222CD. Contemporary clinical trials. 2025 Jun;153:107889. Epub 2025 Mar 25. PMID: 40147544
  • Kircher S, Duan F, An N, Gareen IF, Sicks JD, Sadigh G, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Park ER, Wagner LI, Carlos RC. Patient-Reported Financial Burden of Treatment for Colon or Rectal Cancer. JAMA network open. 2024 Jan 2;7(1):e2350844. PMID: 38194233
  • Sadigh G, Duan F, An N, Gareen ID, Sicks J, Suga JM, Kehn H, Mehan PT, Bajaj R, Hanson DS, Dalia SM, Acoba JD, Yasar DG, Taylor MA, Park E, Wagner LI, Kircher SM, Carlos RC. Financial Hardship Among Patients With Early-Stage Colorectal Cancer. JAMA network open. 2024 Sep 3;7(9):e2431967. PMID: 39287948
  • Wagner LI, Zhao F, Goss PE, Chapman JW, Shepherd LE, Whelan TJ, Mattar BI, Bufill JA, Schultz WC, LaFrancis IE, Nagargoje GG, Vemuri R, Nikcevich DA, Sledge GW, Cella D. Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast cancer research and treatment. 2018 Jun;169(3):537-548. Epub 2018 Feb 17. PMID: 29455298